Bain Capital Life Sciences — 2021 Investments
4 investments dated 2021 · listed companies and verified rows first · show all
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.
BiotechHealthtechWaltham, US
Rene Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Paul Clancy(Director)Daniel Curran(Director)Nancy Hong(Director)
Board seatAndrew Hack· per SEC Form D
Co-investorsBay City CapitalF-Prime CapitalM VenturesMRL Ventures FundRA CapitalRiverVest Venture Partners+4 more
BiotechEmeryville, US
Brian Kotzin(Director)Ian Clark(Director)Ryan Jones(Executive Officer)Karen Walker(Executive Officer)Peter Maag(Executive Officer, Director)James Chung(Executive Officer)
BiotechBurlington, US
Michael Mendelsohn(Executive Officer, Director)
BoardEvan Rachlin(Director)Peter Lawrence(Executive Officer, Director)Edward Mathers(Director)Adam Koppel(Director)in
Board seatNicholas DowningAdam M. Koppel· per SEC Form D
Co-investorsBain CapitalNEA SecondaryPolaris PartnersThird Rock Ventures
HealthtechCambridge, US
Matthew Shair(Director)R. Porter James(Executive Officer, Director)Alex Balcom(Executive Officer)
BoardAndrew Hack(Director)Cameron Wheeler(Director)Joseph Pearlberg(Director)
Co-investorsAvoro Capital Advisors
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.